Mitomycin C in superficial bladder cancer: 24-month follow-up.

Abstract

Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy. At 5 weeks 17 (74%) showed complete disappearance of tumour and 4 (17%) showed a partial response. Twelve months later 8 (35%) remained tumour-free and 15 (65%) had recurrences; 5 of these (22% of all patients) had progressed to invasive cancer. The results at 24 months were little different except that one further patient (27% in all) progressed to invasive cancer. Six patients with symptomatic carcinoma in situ became symptom-free after Mitomycin C, but despite remaining free of symptoms three have progressed to invasive cancer. This small series shows that involvement of large areas of bladder urothelium by tumour, carcinoma in situ and previous therapy for tumour are unfavourable prognostic indices.

Statistics

0200400'87'90'93'96'99'02'05'08'11'14'17
Citations per Year

485 Citations

Semantic Scholar estimates that this publication has 485 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Somerville1985MitomycinCI, title={Mitomycin C in superficial bladder cancer: 24-month follow-up.}, author={Jemma Somerville and Donald W. W. Newling and Blake Richards and Monique R Robinson and Preston H. Smith}, journal={British journal of urology}, year={1985}, volume={57 6}, pages={686-9} }